Novel Rapid Test Developed for Detecting Carbapenemase
By LabMedica International staff writers Posted on 02 Apr 2020 |
Image: The SpectraMax M5 Microplate Reader is the standard for UV/visible multi-mode reader absorbance, providing ultrafast, full spectral range detection for cuvettes, 96-, and 384-well microplates (Photo courtesy of Molecular Devices).
As a potent β-lactamase, carbapenemase can degrade almost all β-lactam antimicrobial drugs, including the carbapenems, regarded as the last line of therapy for many life-threatening infections. If uncontrolled, the spread of these carbapenemases is expected to increase therapeutic failure and leave many patients with no effective treatment options.
Despite the urgency, timely carbapenemase detection remains a challenge for microbiology laboratories. Phenotypic assays are inexpensive and easily performed, but their use requires 24–48 hours and many lack sensitivity or specificity. The widespread use of other assays (e.g., molecular tests of carbapenemase genes, mass spectrometry detection of carbapenem hydrolysis) is impeded by the expertise required to perform them and their cost.
Scientists affiliated with the Massachusetts General Hospital (Boston, MA, USA) demonstrate that by using fluorescence identification of β-lactamase activity (FIBA), carbapenemase production in bacteria can be detected sensitively and specifically in 10 minutes, with only one step. FIBA uses a dark fluorescence probe, β-LEAF (β-lactamase enzyme–activated fluorophore), which turns fluorescent when cleaved by β-lactamases, including penicillinases, extended-spectrum β-lactamases (ESBL), AmpC β-lactamases, and carbapenemases.
The team tested FIBA on 76 randomly selected infection isolates. To start the assay, 25 μL of 1 × 1010 CFU/mL bacterial suspension made by colonies grown overnight on BHI agar is added to each well. To monitor the increase rate, fluorescence measurement is then performed at 37 °C at 10-second intervals for 10 minutes with Ex/Em 450/510 nm in the Spectramax M5 plate reader (Molecular Devices, San Jose, CA, USA).
Genetic test results for β-lactam resistance were provided with the isolates. Among these, 55 were carbapenemase positive, carrying the major epidemic carbapenemase types including Klebsiella pneumoniae carbapenemase, imipenem-hydrolyzing β-lactamase, metallo-β-lactamase, New Delhi metallo-β-lactamase, oxacillinase, Serratia marcescens enzyme, São Paulo metallo-β-lactamase, Verona integron-encoded metallo-β-lactamase, and New Delhi metallo-β-lactamase oxacillinase. The other 21 isolates expressed noncarbapenemase β-lactamases.
The authors concluded that FIBA can be performed ≈10 times faster than the most rapid carbapenemase test commercially available while maintaining comparable sensitivity and specificity. Its automated analysis improves turnaround time and reduces operator variability. With a reagent cost/assay of approximately USD 1.00, FIBA is close in price to phenotypic tests but substantially faster and less labor intensive. The study was published in the April, 2020 issue of the journal Emerging Infectious Diseases.
Related Links:
Massachusetts General Hospital
Molecular Devices
Despite the urgency, timely carbapenemase detection remains a challenge for microbiology laboratories. Phenotypic assays are inexpensive and easily performed, but their use requires 24–48 hours and many lack sensitivity or specificity. The widespread use of other assays (e.g., molecular tests of carbapenemase genes, mass spectrometry detection of carbapenem hydrolysis) is impeded by the expertise required to perform them and their cost.
Scientists affiliated with the Massachusetts General Hospital (Boston, MA, USA) demonstrate that by using fluorescence identification of β-lactamase activity (FIBA), carbapenemase production in bacteria can be detected sensitively and specifically in 10 minutes, with only one step. FIBA uses a dark fluorescence probe, β-LEAF (β-lactamase enzyme–activated fluorophore), which turns fluorescent when cleaved by β-lactamases, including penicillinases, extended-spectrum β-lactamases (ESBL), AmpC β-lactamases, and carbapenemases.
The team tested FIBA on 76 randomly selected infection isolates. To start the assay, 25 μL of 1 × 1010 CFU/mL bacterial suspension made by colonies grown overnight on BHI agar is added to each well. To monitor the increase rate, fluorescence measurement is then performed at 37 °C at 10-second intervals for 10 minutes with Ex/Em 450/510 nm in the Spectramax M5 plate reader (Molecular Devices, San Jose, CA, USA).
Genetic test results for β-lactam resistance were provided with the isolates. Among these, 55 were carbapenemase positive, carrying the major epidemic carbapenemase types including Klebsiella pneumoniae carbapenemase, imipenem-hydrolyzing β-lactamase, metallo-β-lactamase, New Delhi metallo-β-lactamase, oxacillinase, Serratia marcescens enzyme, São Paulo metallo-β-lactamase, Verona integron-encoded metallo-β-lactamase, and New Delhi metallo-β-lactamase oxacillinase. The other 21 isolates expressed noncarbapenemase β-lactamases.
The authors concluded that FIBA can be performed ≈10 times faster than the most rapid carbapenemase test commercially available while maintaining comparable sensitivity and specificity. Its automated analysis improves turnaround time and reduces operator variability. With a reagent cost/assay of approximately USD 1.00, FIBA is close in price to phenotypic tests but substantially faster and less labor intensive. The study was published in the April, 2020 issue of the journal Emerging Infectious Diseases.
Related Links:
Massachusetts General Hospital
Molecular Devices
Latest Microbiology News
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA